Insight towards therapeutic susceptibility of KRAS-mutant cancers from MRTX1257, a novel KRAS G12C mutant-selective small-molecule inhibitor.

被引：0
|
作者：
Christensen, James G. [1 ]
机构：
[1] Mirati Therapeut, San Diego, CA USA
来源：
MOLECULAR CANCER RESEARCH | 2020年 / 18卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IA19
引用
收藏
页码：24 / 24
页数：1
相关论文
共 32 条
  • [1] Insight towards therapeutic susceptibility of KRAS mutant cancers from MRTX1257, a novel KRAS G12C mutant selective small molecule inhibitor
    Christensen, James G.
    Fell, Jay B.
    Marx, Matthew A.
    Fischer, John
    Hallin, Jill
    Calinisan, Andrew
    Baer, Brian
    Burkhard, Michael
    Blake, James
    Vigers, Guy
    Aranda, Ruth
    Hargis, Lauren
    Briere, David
    Engstrom, Lars
    Olson, Peter
    CANCER RESEARCH, 2019, 79 (13)
  • [2] Insight towards therapeutic susceptibility of KRAS mutant cancers from MRTX1257: A prototype selective inhibitor of KRAS G12C.
    Hallin, Jill
    Aranda, Ruth
    Baer, Brian R.
    Briere, David M.
    Burkhard, Michael R.
    Calinisan, Andrew
    Chiang, Harrah
    Engstrom, Lars D.
    Fell, Jay B.
    Fischer, John P.
    Hargis, Lauren
    Marx, Matthew A.
    Olson, Pete
    Sudhakar, Niranjan
    Christensen, James G.
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 64 - 64
  • [3] The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
    Hallin, Jill
    Engstrom, Lars D.
    Hargis, Lauren
    Calinisan, Andrew
    Aranda, Ruth
    Briere, David M.
    Sudhakar, Niranjan
    Bowcut, Vickie
    Baer, Brian R.
    Ballard, Joshua A.
    Burkard, Michael R.
    Fell, Jay B.
    Fischer, John P.
    Vigers, Guy P.
    Xue, Yaohua
    Gatto, Sole
    Fernandez-Banet, Julio
    Pavlicek, Adam
    Velastagui, Karen
    Chao, Richard C.
    Barton, Jeremy
    Pierobon, Mariaelena
    Baldelli, Elisa
    Patricoin, Emanuel F., III
    Cassidy, Douglas P.
    Marx, Matthew A.
    Rybkin, Igor I.
    Johnson, Melissa L.
    Ou, Sai-Hong Ignatius
    Lito, Piro
    Papadopoulos, Kyriakos P.
    Janne, Pasi A.
    Olson, Peter
    Christensen, James G.
    CANCER DISCOVERY, 2020, 10 (01) : 54 - 71
  • [4] Small Molecule Imaging Agent for Mutant KRAS G12C
    Koch, Peter D.
    Quintana, Jeremy
    Ahmed, Maaz S.
    Kohler, Rainer H.
    Weissleder, Ralph
    ADVANCED THERAPEUTICS, 2021, 4 (05)
  • [5] Structure-based drug discovery of MRTX1257: A selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer
    Marx, Matthew
    Baer, Brian
    Ballard, Joshua
    Blake, James
    Bouhana, Karyn
    Briere, David
    Burgess, Laurence
    Burkhard, Michael
    Chiang, Harrah
    Chicarelli, Mark
    Christensen, James
    Fischer, John
    Hallin, Jill
    Mejia, Macedonio
    Olson, Peter
    Savechenkov, Pavel
    Sudhakar, Niranjan
    Tang, Tony
    Vigers, Guy
    Fell, Jay
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [6] The MTA-cooperative PRMT5 inhibitor, MRTX1719, demonstrates increased antitumor activity in combination with KRAS mutant-selective inhibitors in MTAP del,KRAS-mutant cancers
    Waters, Laura
    Aranda, Ruth
    Helu, Xousaen
    Vegar, Laura
    Moya, Krystal
    Calinisan, Andrew
    Hebbert, Allan
    Hallin, Jill
    Vanderpool, Darin
    Briere, David M.
    Christensen, James G.
    Olson, Peter A.
    Engstrom, Lars D.
    CANCER RESEARCH, 2024, 84 (06)
  • [7] Structure-based drug discovery of MRTX1257, a selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer.
    Marx, Matthew A.
    Baer, Brian R.
    Ballard, Joshua
    Blake, James F.
    Bouhana, Karyn
    Briere, David M.
    Burgess, Laurence E.
    Burkhard, Michael R.
    Chiang, Harrah
    Chicarelli, Mark J.
    Christensen, James G.
    Fischer, John P.
    Hallin, Jill
    Mejia, Macedonia J.
    Olson, Peter
    Savechenkov, Pavel
    Sudhakar, Niranjan
    Tang, Tony P.
    Vigers, Guy P.
    Fell, Jay B.
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 67 - 68
  • [8] The identification of MRTX849, a novel KRASG12C inhibitor under clinical investigation, provides insight toward therapeutic susceptibility of KRAS mutant cancers
    Christensen, James G.
    Fell, Jay B.
    Hallin, Jill
    Baer, Brian
    Engstrom, Lars
    Blake, James
    Briere, David
    Ballard, Josh
    Burkhard, Michael
    Fischer, John
    Vigers, Guy
    Aranda, Ruth
    Bowcut, Vickie
    Calinisan, Andrew
    Hargis, Lauren
    Sudhakar, Niranjan
    Marx, Matt
    Olson, Peter
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [9] Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations
    Burns, Timothy F.
    Borghaei, Hossein
    Ramalingam, Suresh S.
    Mok, Tony S.
    Peters, Solange
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (35) : 4208 - 4218
  • [10] Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study
    Kuboki, Yasutoshi
    Murciano-Goroff, Yonina R.
    Yaeger, Rona
    Cassier, Philippe Alexandre
    Heist, Rebecca Suk
    Fujiwara, Yutaka
    Deming, Dustin A.
    Ammakkanavar, Natraj
    Patnaik, Amita
    Shimizu, Toshio
    Call, Justin
    Han, Sae-Won
    Fink, Aaron Alan
    Chen, Aaron
    Willard, Melinda D.
    Balar, Arjun Vasant
    Koyama, Takafumi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 94 - 94
1234